Proof of concept: Performance testing in models

Clinical Microbiology and Infection

Volumn 10, Issue SUPPL. 2, 2004, Pages 12-17

  Craig, W A ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Amoxicillin clavulanate; Animal model; Drug development; Pharmacodynamics; Pharmacokinetics

Indexed keywords

AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; LEVOFLOXACIN; PENICILLIN G;

ANIMAL MODEL; ANTIBIOTIC RESISTANCE; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL STRAIN; COMPUTER SIMULATION; CORRELATION COEFFICIENT; DRUG DESIGN; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RELEASE; DRUG TARGETING; HUMAN; IN VITRO STUDY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PENICILLIN RESISTANCE; PREDICTION; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; STREPTOCOCCUS PNEUMONIAE; SUSTAINED RELEASE FORMULATION;

ANIMALIA; BACTERIA (MICROORGANISMS); STREPTOCOCCUS; STREPTOCOCCUS PNEUMONIAE;

EID: 1942472967     PISSN: 1198743X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1470-9465.2004.00865.x     Document Type: Article

References (24)

1. Ball P, Geddes A, Rolinson G. Amoxycillin clavulanate: an assessment after 15 years of clinical application. J Chemother 1997; 9: 167-198.
2. Calver AD, Walsh NS, Quinn PF et al. Dosing of amoxicillin/clavulanate given every 12 hours is as effective as dosing every 8 hours for treatment of lower respiratory tract infection. Clin Infect Dis 1997; 24: 570-574.
3. Craig WA. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998; 26: 1-12.
4. Forrest A, Nix DE, Ballow CH, Goss TE, Birbingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37: 1073-1081.
5. Preston SL, Drusano GL, Berman AL et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998; 279: 125-129.
6. Andes D, Craig WA. In vivo activities of amoxicillin and amoxicillin-clavulanate against Streptococcus pneumoniae: application to breakpoint determination. Antimicrob Agents Chemother 1998; 42: 2375-2379.
7. Jacobs MR, Felmingham D, Appelbaum PC, Grüneberg RN, The Alexander Project Group. The Alexander Project 1998-2000: susceptibility of pathogens isolated from community-acquired respiratory tract infection to commonly used antimicrobial agents. J Antimicrob Chemother 2003; 52: 229-246.
8. Easton J, Nobel S, Perry CM. Amoxiciliin/clavulanic acid: a review of its use in management of pediatric patients with acute otitis media. Drugs 2003; 63: 311-340.
9. Kaye C, Allen A, Perry S et al. The clinical pharmacokinetics of a new pharmacokinetically enhanced amoxicillin/clavulanate formulation. Clin Ther 2001; 23: 578-584.
10. Löwdin E, Cars O, Odenholt I. Pharmacodynamic studies in an in vitro kinetic model of a new pharmacokinetically enhanced formulation of amoxicillin against Streptococcus pneumoniae with different susceptibilities [abstract P1089]. In: Abstracts from the 12th European Congress of Clinical Microbiology and Infectious Disease. Milan, Italy: European Society for Clinical Microbiology and Infectious Disease. Clin Microbiol Infect 2002; 8 (Suppl. 1): 244.
11. Löwdin E, Cars O, Odenholt I. Pharmacodynamics of amoxicillin/clavulanic acid against Haemophilus influenzae in an in vitro kinetic model: a comparison of different dosage regimens including a pharmacokinetically enhanced formulation. Clin Microbiol Infect 2002; 8: 646-653.
12. MacGowan AP, Bowker KE, Wooten M, Hoff HA. The activity of once a day moxifloxacin against Streptococcus pneumoniae explored using a pharmacodynamic model. Antimicrob Agents Chemother 1999; 43: 1560-1569.
13. Noel AN, MacGowan AP, Bowker KE. Effect of bacterial load on the pharmacodynamic of pharmacokinetically enhanced co-amoxiclav against S. pneumoniae studied in an in vitro model [abstract A-506]. In: Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy. San Diego, CA, USA: American Society for Microbiology, 2002; 6.
14. Casal J, Gimenez CJ, Aguilar L et al. Beta-lactam activity against resistant pneumococcal strains is enhanced by the immune system. J Antimicrob Chemother 2002; 50 (Suppl. 2): 83-86.
15. Woodnutt G, Berry V. Two pharmacodynamic models for assessing the efficacy of amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43: 29-34.
16. Woodnutt G, Berry V. Efficacy of high-dose amoxicillin-clavulanate against experimental respiratory tract infections caused by strains of Streptococcus pneumoniae. Antimicrob Agents Chemother 1999; 43: 35-40.
17. Piroth L, Martin L, Coulon A et al. Development of a new experimental model of penicillin-resistant Streptococcus pneumoniae pneumonia and amoxicillin treatment by reproducing human pharmacokinetics. Antimicrob Agents Chemother 1999; 43: 2484-2492.
18. Craig WA, Redington J, Ebert SC. Pharmacodynamics of amikacin in vitro and in mouse thigh and lung infections. J Antimicrob Chemother 1991; 27 (Suppl. C): 29-40.
19. Berry V. Effect of a pharmacokinetically enhanced formulation of amoxicillin/clavulanate against experimental respiratory tract infection (RTI) in rats caused by Streptococcus pneumoniae [abstract B-988]. In: Abstracts from the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL, USA: American Society for Microbiology, 2001; 53.
20. Vogelman B, Gudmundsson S, Leggett J, Turnidge J, Ebert S, Craig WA. Correlation of antimicrobial pharmacokinetic parameters with therapeutic efficacy in an animal model. J Infect Dis 1988; 158: 831-847.
21. Leggett JE, Fantin B, Ebert S et al. Comparative antibiotic dose-effect relationships at several dosing intervals in murine pneumonitis and thigh-infection models. J Infect Dis 1989; 159: 281-292.
22. Craig WA. Interrelationships between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Drug Microbiol Infect Dis 1995; 22: 89-93.
23. Craig WA. Does the dose matter? Clin Infect Dis 2001; 33 (Suppl. 3): S233-S237.
24. Fantin B, Leggett J, Ebert S, Craig WA. Correlation between in vitro and in vivo activity of antimicrobial agents against gram-negative bacilli in a murine infection model. Antimicrob Agents Chemother 1991; 35: 1413-1422.